ABSTRACT: Introduction: The Cl. NPhys Trial 3 showed that attributes of nerve conduction (NC) were without significant intraobserver differences, although there were significant interobserver differences. Methods: Trial 4 tested whether use of written instructions and pretrial agreement on techniques and use of standard reference values, diagnostic percentile values, or broader categorization of abnormality could reduce significant interobserver disagreement and improve agreement among clinical neurophysiologists. Results: The Trial 4 modifications markedly decreased, but did not eliminate, significant interobserver differences of measured attributes of NC. Use of standard reference values and defined percentile values of abnormality decreased interobserver disagreement and improved agreement of judgment of abnormality among evaluators. Therefore, the same clinical neurophysiologist should perform repeat NCs of therapeutic trial patients. Conclusions: Differences in interobserver judgment of abnormality decrease with use of common standard reference values and a defined percentile level of abnormality, providing a rationale for their use in therapeutic trials and medical practice.
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The need for the Cl. NPhys Trial 4 arose from consideration of the results of Cl. NPhys 3. 1 In Trial 3, 4 expert clinical neurophysiologists and their associate technologists evaluated 8 attributes of nerve conduction (NC) of the leg on 2 consecutive days in 24 masked patients without and with diabetic polyneuropathy. Although their intraobserver agreement was high and not significantly different between days 1 and 2, statistically significant interobserver differences, sometimes of some magnitude, were observed for most attributes of NCs tested. A similar result had been reported earlier by clinical neurophysiologists at Johns Hopkins. 2 Trial 4, similar in design to Cl. NPhys Trial 3, tests whether interobserver differences can be improved or eliminated by standardization of nerve conduction technique, use of common reference values, and setting abnormality at a given percentile value.
METHODS
Conduct of Cl. NPhys Trial 4. The design of Cl. NPhys Trial 4 was similar to that of Trial 3 (same clinical neurophysiologists, same or similar diabetic patients without and with diabetic polyneuropathy, assessment of the same 8 attributes of nerve conduction of the leg, masked evaluation of subjects, and preconditions of testing). In Trial 3, no directions were provided on how to test or judge abnormality of the 8 attributes of NC. In Trial 4, specific testing routines and methods of assessment were provided in a specially prepared syllabus and in a training session.
The same clinical neurophysiologists who had participated in Trial 3 performed the NC tests in Trial 4. They came from 4 different North American medical centers (London, Ontario, Canada; Baltimore, Maryland, USA; Ann Arbor, Michigan, USA; and Rochester, Minnesota, USA). Rather than have the 24 subjects travel from Rochester to the other medical centers for their NC evaluations on 2 consecutive days, we had the smaller group of investigators travel to Rochester, which allowed for a more rigorous and masked trial and a cost savings. Trial 4 patients without and with diabetic polyneuropathy included patients from Trial 3; others were recruited from the Rochester Diabetic Polyneuropathy Study, substituting for patients who had died or who no longer agreed to participate. Two of the 24 patients failed "at the last minute" to participate in Trial 4: 1 because he was snowbound and the other due to intercurrent illness.
Before Trial 4, examiners were sent a syllabus (prepared by W.J.L.) that detailed the specific procedures for the NC studies. The syllabus included descriptions of the requirements for the electromyographic (EMG) instrument; the equipment to be used, including materials for skin preparation, stimulating electrodes, and recording electrodes; and the methods to standardize recording and measurement of the attributes of NC to be evaluated. The NC attributes analyzed were: compound muscle action potential (CMAP) recorded with stimulation at the knee; nerve conduction velocity (MNCV) calculated from the CMAPs recorded with stimulation at the knee and ankle; motor distal latency (MNDL) from the CMAP with ankle stimulation; and sensory nerve action potential amplitude (SNAP) and sensory distal latency (SNDL) from the sural SNAP with stimulation 14.0 cm proximal to the active recording electrode. The 8 NC attributes evaluated were fibular and tibial MNCV, CMAP, and MNDL, and sural SNAP and SNDL.
The training syllabus and the clinical demonstration emphasized skin preparation; precise and standard electrode placement of stimulating, recording, and reference electrodes; techniques to provide optimal stimulation; use of just supramaximal stimulation; recognition of anomalous innervation; description of averaging for certain studies; and standard techniques to measure interelectrode distances and marking of the evoked responses (e.g., baseline to initial negative peak amplitude measurements).
On the day before the start of Cl. NPhys 4, investigators met to review the use of these standard NC techniques. One of us (W.J.L.) demonstrated the specific technique to be followed. All clinical neurophysiologists agreed to follow the exact procedures and techniques outlined in the syllabus. Standard EMG instruments [2 Nicolet EDX Viking (Middleton, Wisconsin) and 1 Cadwell Sierra Wave (Kennewick, Washington)] and peripheral materials were made available for the trial.
On the days of Trial 4 (May 2 and 3, 2013) as in Trial 3, the clinical neurophysiologists and their associate technologist occupied separate cubicles in a large hall. Each subject's legs were carefully pre-warmed in warm water, surface temperatures were measured between evaluations, and limbs were kept warm between evaluations using specially fabricated thermal casts. For NC testing, the lower limbs were introduced through a curtain into the examining cubicle so that the neurophysiologists could not identify the patient by sight. In addition, subjects were asked not to speak to examiners to maintain masking. Each neurophysiology team assessed 8 attributes of NC of the left leg of each of the 22 patients without and with diabetic polyneuropathy, made judgments of normality or abnormality of each attribute assessed, and made an overall judgment of whether the patient had electrophysiologic evidence of polyneuropathy. On the second day, the order of patient assessment was altered, but each of the 4 clinical neurophysiologists assessed the 8 attributes of NC of the 22 patients by performing the same testing procedures and making the same judgments as those on day 1. All visible marks of testing were removed between NC testing of different investigators.
Assessment of Intra-and Interobserver Differences and Agreement. Wilcoxon signed-rank tests were used to test for differences between days 1 and 2. Friedman v 2 or Cochran Q tests were used to assess for interobserver differences. The Krippendorff a was used to assess interobserver agreement. Because there is considerable evidence that neurophysiological functions, such as hearing, vision, and somatic sensation, increase as linear exponential functions, and other neurophysiologic functions may increase similarly, we evaluated interobserver variability using raw neurophysiologic measurements in addition to broader and perhaps more clinically meaningful categories of normality and abnormality. To do this, measured NC data were transformed into normal deviates from percentile values as corrected for applicable physical variables, and they were also transformed into Neuropathy Impairment Score (NIS) points, namely attribute values >5th percentile 5 0 point (normal), 5th to >1st 5 1 point (abnormal), and 1st 5 2 points (highly abnormal). Abnormality of latencies is expressed in the other tail of the normal distribution using the same "points from percentiles" categorization. Table 1 shows the median and range of raw values of the 8 measured attributes of NC assessed in 22 subjects by the 4 groups of clinical neurophysiologists. Using the Friedman v 2 test, statistically significant interobserver differences were found for 10 of 16 comparisons (shown as shaded boxes in Table 1 ). The degree of agreement among clinical neurophysiologists was assessed using the Krippendorff a (e.g., values >0.75 were observed for 10 of 16 evaluations).
Using the Wilcoxon signed-rank test, no statistically significant intraobserver difference was found between days 1 and 2 (footnote to Table 1 ). These results show that, although interobserver differences were observed commonly, there were no significant intraobserver differences between days 1 and 2. Table 2 agreement among clinical neurophysiologists, as measured by the Krippendorff a, averaged 0.72 6 0.19, very similar to the value obtained when Table 3 ).
Judgment of Abnormality of Attributes of NC Using Defined Percentile Abnormalities ( £ 2.5th/ ‡97.5th) from a Standard Reference Source (RDNS-HS). Clinical neurophysiologist measurements of attributes of NC were converted to percentiles and declared to be normal or abnormal by the criterion of 2.5th/ >97.5th based on healthy subject reference values from the RDNS-HS cohort. Using this criterion, statistically significant interobserver differences were observed in 4 of 16 such comparisons (Table  4) . If the percentile criterion was changed to 5th/>95th percentile, interobserver differences among clinical neurophysiologists were found in 3 of 16 such comparisons. When the criterion was changed to 1st/>99th percentile, no significant interobserver disagreement was found, but this latter comparison may be invalid because too few patients had this degree of abnormality to allow valid testing. The agreement among investigators using the Krippendorff a was 0.67 6 0.19. No intraobserver difference was observed between days 1 and 2 (footnote to Table 4 ).
Statistically Significant Interobserver Difference of
Attributes of NC in Trials 3 and 4. Using the designation of D for significant interobserver differences for both days, AD for significant difference on only 1 day, and A (agreement) for no difference for either day, it was possible to compare the frequency of interobserver disagreement between Trials 3 and 4 ( [i.e., clinical neurophysiologist judgment as compared with transformation of their measured values to percentiles and declaring abnormality when fibular MNCV and sural SNAP were 2.5th percentiles based on healthy subject reference values from the RDNS-HS). The degree of agreement among investigators was considerably higher using the latter approach (Table 6 ).
DISCUSSION
Attributes of NC are useful measurements for detection, characterization, and following the course of peripheral neuropathy. They are therefore useful in medical practice, epidemiologic surveys, and therapeutic trials. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] By contrast, because they are physiological measures, they have less value for quantifying the clinical severity of muscle weakness or large-fiber sensory loss, and they typically have no value for characterizing or quantifying small sensory or autonomic fiber dysfunction. Therefore, attributes of NC are generally considered to be surrogate measures of polyneuropathy. 13 Because attributes of NC are quantitative assessments that provide numeric values, it may be assumed that they are reliable indicators of abnormality and have no or low intra-or interrater variability. However, these assumptions are incorrect. Proficiency (accuracy and no or low intra-and interobserver variability) is heavily dependent on how NCs are performed, assessed, and interpreted. NCs can (and may be) performed and interpreted inaccurately. The question of NC proficiency has been tested directly in 2 previous trials utilizing expert clinical neurophysiologists. 2, 14 Neither trial identified significant intraobserver differences in their NC assessments, but they both found significant interobserver differences. Also, some of these interobserver differences were of sufficient magnitude to make it of concern, especially for use in therapeutic trials. The degree of interobserver variability in the 2 trials was surprising, because, in the first, clinical neurophysiologists came from the same medical center and, in the second, investigators had been trained by physicians at the same center.
Trial 4 addressed 2 questions: (1) Could interobserver differences of measured NC attributes be reduced or eliminated by pretrial agreement to use exactly the same techniques of testing? (2) Could judgment of abnormality of individual attributes of NC and clinical neurophysiologic diagnosis of polyneuropathy be improved by use of common reference standards and setting abnormality by defined percentile levels of abnormality? Interobserver differences in assessed measured attributes of NC were less frequent in Trial 4 than in Trial 3. Presumably this decrease related to use of highly standardized techniques of NC assessment. However, one should note that interobserver disagreement was not eliminated. There were still differences in measured attributes of NC abnormality despite rigorous attempts to eliminate them. The fact that intraobserver differences were not found yet interobserver differences were found in all 3 trials suggests that the NC techniques are being performed reproducibly by individual clinical neurophysiologists. However, Trial 4 results also suggest that subtle differences of technique remain despite pre-instruction and agreement on techniques of test performance. Small differences in the EMG instrumentation used may conceivably account for some of the differences observed, but they probably would not explain difference of selective abnormality of some attributes of NC. Are the observed interobserver differences of sufficient magnitude to be of concern for conduct of medical practice or therapeutic trials? For use in medical practice, the small differences observed do not appear to be meaningful clinically (see later), although accurate assessment of NC results with small interobserver differences remains a goal for conduct of both medical practice and therapeutic trials. For therapeutic trials, even very small interobserver differences are of concern, because they decrease the statistical power of a study and may affect the success of a trial. Therefore, our studies support the conclusions of earlier studies 2 that the most optimal therapeutic trial performance results when the same clinical neurophysiologists perform all serial NCs on a given subject.
This trial also demonstrates the value of using common reference values, setting abnormality, and the use of an agreed-upon percentile abnormal value. 15 Interobserver disagreement of judgment of abnormality of individual attributes of NC was reduced using common reference values and defining their abnormality by a given percentile as compared with individual clinical neurophysiologists' judgment. The latter judgments may relate to different reference values among medical centers. These data provide a rationale for use of common reference standards and defined percentile abnormality among EMG laboratories.
Could the choice of subjects explain the observed significant interobserver differences of measured attributes of NC in the Cl. NPhys 3 and 4 Trials? It seems unlikely that the somewhat advanced age of subjects would account for the demonstrated interobserver differences of measured attributes of NC. Conceivably it could have affected judgment of abnormality for individual attributes of NC assessed and for judgment of polyneuropathy. The patients' median age of 70 years required the electrophysiologists to distinguish changes related to "normal" aging from those due to diabetes. This proved challenging, presumably because of limited normative data available to investigators for subjects of advanced age and because the lower limit of normal for some attributes approaches the response detection limit. In this context, median values for sural SNAP amplitudes ranging from 2 to 5 lV represented significant intraobserver differences, but are unlikely to represent a physiologically important difference, emphasizing the use of broader categories of NC abnormality based on standard reference values corrected for applicable variables.
This trial (Cl. NPhys 4) is the part of a series of trials by our group aimed at assessing the proficiency of neuropathy signs (Trials 1 and 2) , attributes of NC (Trial 3 and this trial), quantitative sensation testing (Trial 5), and perhaps others. 14, 16, 17 Proficiency testing is now expected in the assessment of most laboratory tests. Such proficiency testing has not been required of clinical assessments of neuropathy symptoms and signs or of clinical neurophysiologic tests, presumably due to the impracticality. For laboratory proficiency testing, it is possible to send a small sample of serum or tissue to a reference or multiple reference laboratories, which can be done on multiple occasions and on a continuing basis. The same proficiency procedures cannot be followed for assessment of patients' examinations. However, it is possible, as shown in our Cl. NPhys trials, to do proficiency testing occasionally to assess critically the proficiency of physician clinical or neurophysiology test assessments.
